Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease

NCT00246090 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00246090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00246090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
September 30, 2007
Enrollment
298 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer